Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis.

Trial Profile

Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Teriparatide (Primary) ; Raloxifene
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms EUROFORS
  • Most Recent Events

    • 04 Jun 2009 Results from substudy 2 have been reported in the Journal of Bone and Mineral Research.
    • 04 Jun 2009 Primary endpoint 'Lumbar spine bone mineral density' has been met.
    • 27 Jul 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top